W Wendell Cheatham Net Worth

The estimated Net Worth of W Wendell Cheatham is at least $1.84 Tysiąc dollars as of 28 July 2004. W Cheatham owns over 300 units of Mannkind Corp stock worth over $1,839 and over the last 20 years W sold MNKD stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

W Cheatham MNKD stock SEC Form 4 insiders trading

W has made over 1 trades of the Mannkind Corp stock since 2004, according to the Form 4 filled with the SEC. Most recently W bought 300 units of MNKD stock worth $1,260,000 on 28 July 2004.

The largest trade W's ever made was buying 300 units of Mannkind Corp stock on 28 July 2004 worth over $1,260,000. On average, W trades about 150 units every 0 days since 2004. As of 28 July 2004 W still owns at least 300 units of Mannkind Corp stock.

You can see the complete history of W Cheatham stock trades at the bottom of the page.

What's W Cheatham's mailing address?

W's mailing address filed with the SEC is 28903 NORTH AVENUE PAINE, , VALENCIA, CA, 91355.

Insiders trading at Mannkind Corp

Over the last 20 years, insiders at Mannkind Corp have traded over $14,187,027 worth of Mannkind Corp stock and bought 107,212,962 units worth $2,707,661,837 . The most active insiders traders include Alfred E Mann, Juergen Martens oraz David Thomson. On average, Mannkind Corp executives and independent directors trade stock every 27 days with the average trade being worth of $3,220,647. The most recent stock trade was executed by Stuart A Tross on 3 September 2024, trading 25,000 units of MNKD stock currently worth $156,500.

What does Mannkind Corp do?

mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.

Complete history of W Cheatham stock trades at Mannkind Corp

Mannkind Corp executives and stock owners

Mannkind Corp executives and other stock owners filed with the SEC include:

• Michael Castagna,
  Chief Executive Officer, Director
• Dr. Michael E. Castagna Pharm.D.,
  CEO & Director
• Stuart Tross,
  Chief People and Workplace Officer
• David Thomson,
  Executive Vice President, General Counsel, Secretary
• Dr. Michael E. Castagna,
  CEO & Director
• Steven Binder,
  Chief Financial Officer
• Dr. David B. Thomson,
  Exec. VP, Gen. Counsel & Sec.
• Joseph Kocinsky,
  Chief Technology Officer
• Steven B. Binder,
  Chief Financial Officer
• Joseph Kocinsky M.B.A., M.S.,
  Chief Technology Officer
• Dr. Stuart A. Tross,
  Chief People & Workplace Officer
• Rosabel Alinaya,
  Vice President of Investor Relations, Interim Corporate Controller, Treasurer
• Christine Mundkur,
  Independent Director
• Kent Kresa,
  Independent Chairman of the Board
• Ronald Consiglio,
  Independent Director
• Michael Friedman,
  Independent Director
• James Shannon,
  Independent Director
• Kevin Kaiserman,
  Vice President - Medical Affairs and Safety
• Jennifer Grancio,
  Independent Director
• Anthony Hooper,
  Independent Director
• Alejandro Galindo M.B.A., M.S.,
  Chief Commercial Officer
• James Patrick McCauley Jr., J.D., M.B.A.,
  Chief Commercial Officer
• John F. Bedard,
  Sr. VP of Worldwide Regulatory Affairs
• Rosabel Realica Alinaya,
  VP of Investor Relations & Treasury
• Thomas Hofmann M.D., Ph.D.,
  Chief Scientific Officer
• Matthew J Pfeffer,
  Corporate VP and CFO
• Henry L Nordhoff,
  Director
• David Mac Callum,
  Director
• Raymond W. Urbanski,
  Corp VP, CMO
• David M Kendall,
  Chief Medical Officer
• Elizabeth Garrett Ingram,
  Chief Marketing Officer
• Courtney Barton,
  Chief Compl & Privacy Officer
• Patrick Mc Cauley,
  Chief Commercial Officer
• John R. Riesenberger,
  VP & Chief Commercial Officer
• Richard L Anderson,
  VP & CFO
• Heather Hay Murren,
  Director
• Kathleen Connell,
  Director
• Llew Keltner,
  Director
• Dan Burns,
  VP & President, MKBP
• W Wendell Cheatham,
  VP, Medical & Reg Affairs
• Juergen Martens,
  Corporate VP
• Hakan Edstrom,
  President & COO
• Alfred E Mann,
  Chairman & CEO
• Diane Palumbo,
  Vice President, Human Resource
• Abraham E Cohen,
  Director
• Peter C Richardson,
  Chief Scientific Officer
• Lauren M Sabella,
  EVP Chief Operating Officer
• Alejandro Galindo,
  EVP Endocrine Business Unit
• Burkhard Blank,
  EVP Chief Medical Officer
• Sanjay R Singh,
  EVP Technical Operations
• Christopher B Prentiss,
  Chief Financial Officer
• Sabrina Kay,